---
document_datetime: 2023-09-21 20:45:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_en.pdf
document_name: ronapreve-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7583889
conversion_datetime: 2025-12-31 04:11:43.856193
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength              | Pharmaceutical Form             | Route of Administration           | Immediate Packaging   | Content (concentration)                 | Pack size                               |
|------------------|-------------------|-----------------------|---------------------------------|-----------------------------------|-----------------------|-----------------------------------------|-----------------------------------------|
| EU/1/21/1601/001 | Ronapreve         | 300 mg / 300 mg       | Solution for injection/infusion | Intravenous use, Subcutaneous use | vial (glass)          | 2.5 ml (120 mg/ml) + 2.5 ml (120 mg/ml) | 1 single dose vial + 1 single dose vial |
| EU/1/21/1601/002 | Ronapreve         | 120 mg/ml / 120 mg/ml | Solution for injection/infusion | Intravenous use, Subcutaneous use | vial (glass)          | 11.1 ml + 11.1 ml                       | 1 multidose vial + 1 multidose vial     |